Literature DB >> 33259885

Tumor microenvironment as a therapeutic target in cancer.

Yi Xiao1, Dihua Yu2.   

Abstract

Tumor microenvironment denotes the non-cancerous cells and components presented in the tumor, including molecules produced and released by them. The constant interactions between tumor cells and the tumor microenvironment play decisive roles in tumor initiation, progression, metastasis, and response to therapies. The tumor microenvironment as a therapeutic target in cancer has attracted great research and clinical interest. Here we summarize the current progress in targeting the tumor microenvironment in both drug development and clinical trials; highlight challenges in targeting the tumor microenvironment to achieve therapeutic efficacy; explore new technologies and approaches to better decipher the tumor microenvironment; and discuss strategies to intervene in the pro-tumor microenvironment and maximize therapeutic benefits. Published by Elsevier Inc.

Entities:  

Keywords:  Drug; Resistance; Target; Therapy; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33259885      PMCID: PMC8084948          DOI: 10.1016/j.pharmthera.2020.107753

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  187 in total

Review 1.  Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.

Authors:  D Ciardiello; E Elez; J Tabernero; J Seoane
Journal:  Ann Oncol       Date:  2020-07-23       Impact factor: 32.976

2.  TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.

Authors:  Penka S Petrova; Natasja Nielsen Viller; Mark Wong; Xinli Pang; Gloria H Y Lin; Karen Dodge; Vien Chai; Hui Chen; Vivian Lee; Violetta House; Noel T Vigo; Debbie Jin; Tapfuma Mutukura; Marilyse Charbonneau; Tran Truong; Stephane Viau; Lisa D Johnson; Emma Linderoth; Eric L Sievers; Saman Maleki Vareki; Rene Figueredo; Macarena Pampillo; James Koropatnick; Suzanne Trudel; Nathan Mbong; Liqing Jin; Jean C Y Wang; Robert A Uger
Journal:  Clin Cancer Res       Date:  2016-11-17       Impact factor: 12.531

Review 3.  Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis.

Authors:  Napoleone Ferrara
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

Review 4.  Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.

Authors:  W Nathaniel Brennen; John T Isaacs; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2012-02       Impact factor: 6.261

5.  Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death.

Authors:  Marie Wislez; Nathalie Rabbe; Joëlle Marchal; Bernard Milleron; Bruno Crestani; Charles Mayaud; Martine Antoine; Paul Soler; Jacques Cadranel
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

6.  IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.

Authors:  Florian R Greten; Lars Eckmann; Tim F Greten; Jin Mo Park; Zhi-Wei Li; Laurence J Egan; Martin F Kagnoff; Michael Karin
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

7.  Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.

Authors:  Adam W Studebaker; Gianluca Storci; Jillian L Werbeck; Pasquale Sansone; A Kate Sasser; Simona Tavolari; Tim Huang; Michael W Y Chan; Frank C Marini; Thomas J Rosol; Massimiliano Bonafé; Brett M Hall
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

8.  Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.

Authors:  Antonio Jimeno; Glen J Weiss; Wilson H Miller; Scott Gettinger; Bernard J C Eigl; Anne Lynne S Chang; Joi Dunbar; Shannon Devens; Kerrie Faia; Georgios Skliris; Jeff Kutok; Karl D Lewis; Raoul Tibes; William H Sharfman; Robert W Ross; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2013-04-10       Impact factor: 12.531

9.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors:  David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

Review 10.  Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer.

Authors:  Carlo V Hojilla; Geoffrey A Wood; Rama Khokha
Journal:  Breast Cancer Res       Date:  2008-03-31       Impact factor: 6.466

View more
  42 in total

1.  PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer.

Authors:  Xinwei Li; Yongfei Fan; Mingyue Tang; Huiyuan Li; Yue Zhang; Jiaqi Mi; Yanyan Wang; Menglin Zhao; Zishu Wang; Fang Su
Journal:  J Inflamm Res       Date:  2022-09-16

2.  Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics.

Authors:  Marwa A Abd El-Azeem; Mona A Ali; Safinaz H El-Shorbagy
Journal:  J Egypt Natl Canc Inst       Date:  2022-09-26

Review 3.  Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis?

Authors:  Safak Guel-Klein; Miguel Enrique Alberto Vilchez; Wim Ceelen; Beate Rau; Andreas Brandl
Journal:  Visc Med       Date:  2022-03-21

4.  A Cell Component-Related Prognostic Signature for Head and Neck Squamous Cell Carcinoma Based on the Tumor Microenvironment.

Authors:  Siyu Li; Yajun Gu; Junguo Wang; Dengbin Ma; Xiaoyun Qian; Xia Gao
Journal:  Int J Genomics       Date:  2022-06-25       Impact factor: 2.758

Review 5.  Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.

Authors:  Sen Liu; Xu Chen; Tianxin Lin
Journal:  J Adv Res       Date:  2021-11-24       Impact factor: 12.822

6.  A Systematic Pan-Cancer Analysis of CASP3 as a Potential Target for Immunotherapy.

Authors:  Zheng Zhou; Shiying Xu; Liehao Jiang; Zhuo Tan; Jiafeng Wang
Journal:  Front Mol Biosci       Date:  2022-04-29

7.  Identification and Validation of a Novel Immune Infiltration-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma by Machine-Learning Strategies.

Authors:  Xuli Guo; Hailin Xiong; Shaoting Dong; Xiaobing Wei
Journal:  Gastroenterol Res Pract       Date:  2022-06-14       Impact factor: 1.919

8.  Exosomes From Cancer-Associated Mesenchymal Stem Cells Transmit TMBIM6 to Promote the Malignant Behavior of Hepatocellular Carcinoma via Activating PI3K/AKT Pathway.

Authors:  Chuzhi Shang; Mi Ke; Lin Liu; Cong Wang; Yufang Liu; Xin Zheng
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

9.  DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas.

Authors:  Xiaojing Chang; Jie Pan; Ruoyu Zhao; Tianfang Yan; Xinrui Wang; Cunle Guo; Yining Yang; Guohui Wang
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 10.  Application of Nano-Drug Delivery System Based on Cascade Technology in Cancer Treatment.

Authors:  Ying Sun; Xiaoli Ma; Hao Hu
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.